Abivax Sees Unusually High Options Volume (NASDAQ:ABVX)

Abivax SA Sponsored ADR (NASDAQ:ABVX) was the recipient of some unusual options trading activity on Tuesday. Stock investors acquired 6,598 call options on the stock. This is an increase of approximately 89% compared to the typical daily volume of 3,492 call options.

Abivax Price Performance

ABVX traded down $2.12 during midday trading on Tuesday, reaching $138.28. 1,355,757 shares of the company’s stock were exchanged, compared to its average volume of 884,306. The firm has a market capitalization of $10.78 billion, a price-to-earnings ratio of -33.08 and a beta of 0.49. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.03. Abivax has a one year low of $4.77 and a one year high of $148.83. The business has a 50-day simple moving average of $114.53 and a two-hundred day simple moving average of $78.02.

Abivax (NASDAQ:ABVX) last issued its earnings results on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The firm had revenue of ($4.92) million for the quarter. As a group, research analysts predict that Abivax will post -2.83 EPS for the current year.

Institutional Trading of Abivax

Several hedge funds have recently modified their holdings of the stock. Bank of America Corp DE increased its holdings in shares of Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after purchasing an additional 1,990 shares in the last quarter. Cubist Systematic Strategies LLC increased its stake in shares of Abivax by 34.3% in the 1st quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock valued at $63,000 after buying an additional 2,595 shares during the period. Nantahala Capital Management LLC raised its position in shares of Abivax by 3.3% during the first quarter. Nantahala Capital Management LLC now owns 1,482,994 shares of the company’s stock worth $9,269,000 after acquiring an additional 46,947 shares during the last quarter. Paloma Partners Management Co acquired a new position in shares of Abivax during the first quarter valued at $240,000. Finally, ADAR1 Capital Management LLC boosted its holdings in Abivax by 46.0% in the first quarter. ADAR1 Capital Management LLC now owns 2,210,019 shares of the company’s stock valued at $13,813,000 after acquiring an additional 696,626 shares during the last quarter. 47.91% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ABVX has been the topic of a number of recent research reports. Guggenheim restated a “buy” rating and set a $175.00 price target on shares of Abivax in a report on Thursday, December 18th. Wolfe Research raised Abivax to a “strong-buy” rating in a research report on Thursday, November 6th. Citizens Jmp upped their price target on Abivax from $114.00 to $131.00 and gave the stock a “market outperform” rating in a research note on Tuesday, December 16th. Truist Financial set a $140.00 target price on Abivax in a report on Monday, November 24th. Finally, BTIG Research upped their price target on shares of Abivax from $112.00 to $120.00 and gave the company a “buy” rating in a report on Monday, October 6th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $128.73.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.